New ArrayPlate measures four genes in each well of a 384-well plate. ArrayPlate 384-4 quantifies RNA expression levels in cells treated with potential new drugs with high sample throughput, 10,000 or more samples per hour, and whole assay CV's of less than 10%. The 384-4 platform is based on HTG Inc.'s self-customized quantitative Nuclease Protection Assay (qNPA), which allows researchers to test any sample type, including fixed tissue, using small sample sizes, while avoiding the need for extraction, reverse transcription or amplification. Sensitivity is sufficient to measure even low abundant genes. Researchers are able to select a set of genes for simultaneous evaluation, a critical step in identifying the most promising drug compounds to treat complex, multi-factorial diseases. The 384-4 multiplexing capabilities can exploit the power of gene signatures to reduce the whole cell assay false positive rate to as little as 0.05 percent, permitting discovery of weakly active compounds that would otherwise be missed. The product consists of a user-customizable plate with four elements of anchor oligonucleotides printed at the bottom of each well. Combined with the ability to fully automate qNPA using off-the-shelf automation hardware, the 384-4 technology permits the acquisition of 40,000 or more discrete gene measurements per hour.